# Egon Pfarr

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/egon-pfarr/

## Facts

| Field | Value |
| --- | --- |
| Citations | 95 |
| Field | Diabetes Treatment and Management |
| h-index | 3 |
| i10-index | 2 |
| Last Known Institution | Boehringer Ingelheim (Germany) |
| OpenAlex ID | https://openalex.org/A5045500957 |
| Works | 10 |

## Researcher papers

- [Therapeutic Use of the Natriuretic Peptide Ularitide in Acute Renal Failure](https://scholariq.org/papers/therapeutic-use-of-the-natriuretic-peptide-ularitide-in-acute-renal-failure/)
- [Effect of reteplase on hemostasis variables: analysis of fibrin specifity, relation to bleeding complications and coronary patency](https://scholariq.org/papers/effect-of-reteplase-on-hemostasis-variables-analysis-of-fibrin-specifity/)
- [EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE](https://scholariq.org/papers/empagliflozin-reduces-mortality-and-hospitalization-for-heart-failure-in/)
- [Thrombolytic therapy in acute massive pulmonary embolism Double bolus reteplase versus conventional alteplase infusion in a randomized controlled trial](https://scholariq.org/papers/thrombolytic-therapy-in-acute-massive-pulmonary-embolism-double-bolus-reteplase/)
- [Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial](https://scholariq.org/papers/empagliflozin-reduces-risk-of-hospitalization-in-patients-with-chronic-kidney/)
- [Effect of empagliflozin on all-cause hospitalization in EMPA-KIDNEY](https://scholariq.org/papers/effect-of-empagliflozin-on-all-cause-hospitalization-in-empa-kidney/)
- [Retrospective observational study on the treatment of multiple sclerosis: ACT – Adherence Counts for successful Treatment: Adherence on therapy in patients receiving immunomodulating first line treatment factors influencing adherence on the treatment](https://scholariq.org/papers/retrospective-observational-study-on-the-treatment-of-multiple-sclerosis-act/)
- [388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial](https://scholariq.org/papers/388-p-interrelationship-between-hypoglycemia-and-cv-and-mortality-outcomes-in/)
- [952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial](https://scholariq.org/papers/952-p-incident-and-recurrent-hypoglycemia-with-linagliptin-and-glimepiride-in/)
- [Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial](https://scholariq.org/papers/interrelationship-between-hypoglycemia-and-cv-and-mortality-outcomes-in-type-2/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)

## Researcher university

- [Boehringer Ingelheim (Germany)](https://scholariq.org/institutions/boehringer-ingelheim-germany/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.